The Effects of Acetylsalicylic Acid on Immunoparalysis Following Human

Status Completed

Clinical Trial Summary

Rationale:

The last years, research focus has moved to immunostimulatory agents in order to restore or increase the functionality of the immune system during sepsis-induced immunoparalysis. Epidemiologic data show that prehospital use of low dose acetylsalicylic acid (ASA) is associated with improved outcome of sepsis. Experimental data indicate that ASA exerts pro-inflammatory effects during systemic inflammation. However, it remains to be determined whether treatment with ASA improves immune function once immunoparalysis has developed and whether prehospital use of low dose ASA prevents the development of immunoparalysis. In the former case, ASA is a potential immunostimulatory therapy that can treat sepsis-induced immunoparalysis. In the latter case, ASA may have a broader indication as an immunomodulating agent. Taken together, ASA might be a promising, cheap, well-known, and globally available agent to reduce the incidence of secondary infections and improve patient outcome in sepsis.

Objective:

- To determine whether acetylsalicylic acid treatment can reverse endotoxin tolerance, which is expressed as a decrease in pro-inflammatory cytokine levels between the first and second endotoxin challenge.

- To determine whether acetylsalicylic acid prophylaxis can prevent endotoxin tolerance, which is expressed as a decrease in pro-inflammatory cytokine levels between the first and second endotoxin challenge.

Study design:

Double-blind randomized placebo-controlled pilot study in 30 healthy male volunteers during repeated experimental endotoxemia. All subjects will receive a 14 day course of study medication (low-dose ASA or placebo) and undergo experimental endotoxemia (lipopolysacharide (LPS), E.Coli type O113) on day 7 and on day 14. LPS is administrated using an initial bolus of 1ng/kg followed by continuous infusion at 1ng/kg/hr during 3 hours.

Subjects are randomized in three study arms:

1. Treatment group: 7 days placebo / first endotoxemia / 7 days ASA 80 mg (loading dose on first day of 160mg) / second endotoxemia

2. Prophylaxis group: 7 days ASA 80 mg (loading dose on first day of 160mg) / first endotoxemia / 7 days ASA 80 mg / second endotoxemia

3. Placebo group: 7 days placebo / first endotoxemia / 7 days placebo / second endotoxemia

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Endotoxemia

Clinical Trial Details

NCT number	NCT02922673
Study type	Interventional
Source	Radboud University
Contact
Status	Completed
Phase	N/A
Start date	September 2016
Completion date	September 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04117802` - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome	N/A
Completed	`NCT01766414` - In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR II	Phase 3
Completed	`NCT04130321` - Demonstration of the Prebiotic-like Effects of Camu-camu Consumption Against Obesity-related Disorders in Humans	N/A
Completed	`NCT02612480` - Ticagrelor in Human Endotoxemia Response to Human Endotoxemia	N/A
Completed	`NCT01474629` - Probiotic Sport Study	N/A
Completed	`NCT00246714` - Pathophysiology and Clinical Relevance of Endotoxin Tolerance in Humans	Phase 1
Recruiting	`NCT06147440` - Different Dietary Patterns	N/A
Recruiting	`NCT03901807` - Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study	N/A
Completed	`NCT03754504` - Effects of Cranberry Powder Supplements on Gut Microbiota Diversity and Metabolic Syndrome	N/A
Completed	`NCT03800277` - Effect of Cranberry and Agaves Extract on Microbiota and Intestinal Health	N/A
Completed	`NCT00785018` - In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia	N/A
Recruiting	`NCT00413348` - Type 2 Diabetes and the Effect of Probiotics	N/A
Recruiting	`NCT00413465` - Study of Renal Blood Flow During Human Endotoxemia	N/A
Completed	`NCT00412906` - Study of Gene Activity in Fat and Muscle in Diabetics and Healthy Controls	N/A
Completed	`NCT05752968` - Elevated Levels of Antibodies to Endotoxin Core in Hemodialysis Patients With Peripheral Artery Disease
Completed	`NCT01374711` - The Effects of Immunostimulation With GM-CSF or IFN-y on Immunoparalysis Following Human Endotoxemia	N/A
Completed	`NCT00916448` - The Effects of Atazanavir-induced Hyperbilirubinemia During Human Endotoxemia	N/A
Completed	`NCT00332267` - Cerebral Blood Flow and Metabolism During Hypoxia and Endotoxemia	N/A
Completed	`NCT03482284` - Effect of Monosaccharides on Intestinal Barrier Function	N/A
Completed	`NCT03972878` - Foodprint 1.0: Physiological Acute Responses After Consumption of Confectionary Products	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The Effects of Acetylsalicylic Acid on Immunoparalysis Following Human Endotoxemia — SALYCENDO

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms